During the last three months, 9 analysts shared their evaluations of Agilon Health AGL, revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 1 | 6 | 1 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 1 | 1 | 3 | 1 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Agilon Health, presenting an average target of $6.83, a high estimate of $9.00, and a low estimate of $5.00. Observing a downward trend, the current average is 29.08% lower than the prior average price target of $9.63.
Decoding Analyst Ratings: A Detailed Look
The analysis of recent analyst actions sheds light on the perception of Agilon Health by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jailendra Singh | Truist Securities | Raises | Hold | $6.50 | $6.40 |
| Craig Jones | Stifel | Lowers | Hold | $7.00 | $8.00 |
| Daniel Grosslight | Citigroup | Announces | Neutral | $6.00 | - |
| Andrew Mok | Barclays | Announces | Underweight | $5.00 | - |
| Jailendra Singh | Truist Securities | Lowers | Hold | $7.50 | $10.00 |
| Bill Sutherland | Benchmark | Lowers | Buy | $9.00 | $13.00 |
| Elizabeth Anderson | Evercore ISI Group | Lowers | In-Line | $6.00 | $7.00 |
| Sean Dodge | RBC Capital | Lowers | Outperform | $8.00 | $11.00 |
| Gary Taylor | TD Cowen | Lowers | Market Perform | $6.50 | $12.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Agilon Health. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Agilon Health compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Agilon Health's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Agilon Health's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Agilon Health analyst ratings.
Delving into Agilon Health's Background
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
Understanding the Numbers: Agilon Health's Finances
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Agilon Health's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 52.17%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Agilon Health's net margin is impressive, surpassing industry averages. With a net margin of -0.38%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Agilon Health's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.9% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Agilon Health's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.3%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Agilon Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.07.
How Are Analyst Ratings Determined?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
